PDL BioPharma

PDL BioPharma, Inc. announced today it has received a facsimile letter from Genentech asserting that Avastin®, Herceptin®, Lucentis® and Xolair® do not infringe supple...

PDL BioPharma, Inc. announced today that it has completed the retirement of $61.7 million in aggregate principal amount of the Company's outstanding 2.75% Converti...

PDL BioPharma, Inc. today announced that Christine Larson, the company's vice president and chief financial officer, will present at the 2010 Global Hunter Securit...

PDL BioPharma, Inc. announced today that it has entered into separate privately negotiated agreements under which it will retire $61.6 million in aggregate principal am...

PDL BioPharma, Inc. today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the BMO Capital Markets' 10t...

PDL BioPharma, Inc. today reported financial results for the second quarter ended June 30, 2010.

PDL BioPharma, Inc. today announced that the Company will release its second quarter financial results on Wednesday, July 28, 2010 after the markets close. PDL's m...